8 ms·
Biopharma has abandoned antibiotic development
- tomohawk 7y ago> Under the Affordable Care Act, hospitals must pay a penalty for each hospital-acquired-infection (HAI) occurring within their in-patient population. As a result, if a patient dies from a superbug contracted during a procedure such as surgery, the official cause of death may be instead listed as “Complications from Surgery.” Consistent and systemic undercounting of illnesses and deaths from resistant infections further discourages the development of new antibiotics as the number of patients who need these medicines may appear to be very small. Sounds like the regulatory environment is overriding any market forces or customer needs.
- crooked-v 7y ago> Consistent and systemic undercounting of illnesses and deaths from resistant infections That's not "regulatory environment goes too far", that's "regulatory environment doesn't go far enough".
- quotemstr 7y agoPick any problem that regulation causes and you'll find some people saying that the real problem is that the regulation doesn't go far enough. You can listen to these people and expand regulation an indefinite number of times until you end up with a full command economy --- and we all know how well command economies work.
- xupybd 7y agoPoorly crafted regulation tends to cause more harm than good. That's why turning to regulation as the solution must be done with care. On the other side. Unrestrained markets tend to do more harm than good. That's why turning away from regulation must be done with care.
- sddfd 7y agoTldr: privately funded research is not working. I don't understand why antibiotics research can't be done at (publicly funded) universities?
- tomohawk 7y ago> Approval incentives were not the only policy included in the GAIN Act. There were also measures designed to promote stewardship, or appropriate use, of new antibiotics. In short, when a new antibiotic becomes available, it should only be used as a last resort to prevent new resistance from arising. This kind of responsible use is a good thing! But stewardship severely limits the number of patients who will receive a new antibiotic and, correspondingly, the potential sales volume. Privately funded research is unable to overcome the well intentioned regulations that are preventing use of the antibiotics that are developed. Instead of hoarding the few antibiotics we have, we should be moving faster and keeping ahead of the problem, but the current regulations essentially prohibit that.
- zozbot234 7y agoIt's comparatively difficult to do applied research with grant funding, which is what most "publicly funded" universities tend to rely on. For this sort of high-value research, what you want is prizes so that success can be rewarded after the fact, even when the usual "market" mechanism of selling drugs is not working very well for whatever reason. Current policy approaches provide 'development incentives' of some sort as OP mentions, but clearly these are not enough.
- jdkee 7y agoFrom the article, "Public measures designed to incentivize development of new antibiotics are woefully inadequate." This is the issue. Relying on private entities to provide (R&D, clinical trials) for what are ostensibly public goods (antibiotic resistant bugs puts every person at risk) brings the real risk of market failure. The NIH is making some progress on this front. https://aspe.hhs.gov/system/files/pdf/258516/ProgressYears1and2CARBNationalActionPlan.pdf https://aspe.hhs.gov/system/files/pdf/258516/ProgressYears1a... It appears that overprescribing existing antibiotics to people and livestock is a leading cause of rising drug resistance, both of which can be addressed by policy changes.
- mark-r 7y ago> It appears that overprescribing existing antibiotics to people and livestock is a leading cause of rising drug resistance, both of which can be addressed by policy changes. I worry that any changes in that area will be too little too late.
- iambateman 7y agoIt seems like overprescribing to a cow is such low hanging fruit. I understand that if my 5-day-old child marginally needs antibiotics, that the doctor may prescribe to appear active. But couldn’t sensible legislation end over-prescription to livestock overnight? Is this really an issue of beating the cow lobby?
- dv_dt 7y agoThe "cow lobby" is large multinational corporations... so yes it's an issue beating their lobbyists. Also, a side effect of antibiotics is weight gain in livestock - so even legislation that ostensibly outlaws use for the direct purpose of directly adding to profits, language in regulation is generally kept for medical purposes of "reducing disease" among herds. Disease that is at a high rate because of high density feedlot practices...
- yabadabadoes 7y agoI think a weight loss factor could be added to legal antibiotics to remove the benefits of their overuse.. Caffeinated cows on a rampage might correct the industry.
- AtlasBarfed 7y agoA typical failing of short term economic thinking: Superbugs are virtually certain to kill a huge number of people, because virulent resistant strains gonna Black Death. But we can't get a payoff within a quarter or whatever the payoff window for the seed money is? Eh, don't bother investing. This is where the government must step in. Oh right, gubberment baaaad. Seriously, if these have promise they should be funded for 10 years by a multinational conglomerate. I mean, maybe the Chinese government will step in. You know, the only forward-thinking major government in the world? What a world.
- LinuxBender 7y agoI would not be surprised if DARPA were already in this space. They have been researching the affects of Sulforaphane on reversing autism in children. Surely they must have teams of people working on antibiotics. Are there any scientists here from DARPA that can chime in?
- sithadmin 7y agoThe DoD has the DTRA (Defense Threat Reduction Agency) Chemical and Biological Technologies Directorate, which throws funding at things like antibiotics development. Achaogen, mentioned in the blog post here, has received DTRA funding in the past. BARDA (a US HHS program) is also a huge player in this space.
- refurb 7y agoYou're missing the main point of the article. If you invent a great new antibiotic, it won't be used unless absolutely necessary.
- ur-whale 7y agoThis is a great summary of the article and should be the top comment.
- natalyarostova 7y agoIf you write less obnoxiously you would be more likely to convince people of your ideas. Otherwise what's the point?
- heavyset_go 7y agoThe healthcare and pharmaceutical industries sure seem to have a lot of market failures.
- DoreenMichele 7y agoA reminder: Poor sanitation in underdeveloped countries is part of what is breeding antibiotic resistant infections which then get exported to more developed countries thanks to the modern ability to get from pretty much anywhere on the planet to pretty much anywhere else on the planet that people typically reside in about 24 hours (or less). The last time I said this, someone apparently thought I was being racist and classist and saying mean things about "those people" overseas. I'm not. I'm saying there are other ways to tackle this issue and one is by supporting hygiene programs worldwide, including here in the US when the revival of sometimes deadly Medieval Diseases is associated with the homeless crisis we are having.
- opwieurposiu 7y agoGates foundation is working on toilets to remediate this exact problem. https://www.gatesfoundation.org/what-we-do/global-growth-and-opportunity/water-sanitation-and-hygiene/reinvent-the-toilet-challenge-and-expo https://www.gatesfoundation.org/what-we-do/global-growth-and...
- quotemstr 7y ago> Poor sanitation in underdeveloped countries It's not just poor sanitation. It's that in underdeveloped countries antibiotics are completely uncontrolled, available without a prescription for almost nothing. This availability promotes misuse.
- zozbot234 7y agoBetter sanitation and hygiene would help with that as well, though. People would no longer get sick with lots of infections that can easily be prevented in other ways, and the habit of overprescribing antibiotics would disappear.
- quotemstr 7y agoPeople take antibiotics prophylactically all the time even here in the US. They'll do so in the developing world too unless stopped with regulation restricting use of antibiotics to cases where they'll be effective.
- xupybd 7y agoIf the public knew about this problem, if it were marketed to them there might be a solution. You'd likely need some policy changes too. But if I could choose between an insurance that supported and supplied new antibiotics I'd jump at that insurance over one that did not. I'd happily pay more to be covered for something so fundamental. Obviously there would be a lot to iron out but I think there is an opportunity for health insurance companies to make a good amount of money off of that. I'm guessing however that existing policy would make this impossible.
- Starkus 7y agoAh, reminds me of investing (poorly) in Amplify Biosciences in late 2017... Since acquired by Armata pharma, which trades around 4 a share, cap of 40M.... I lost 90% of my investment, oh darn, was a bad investment in hindsight. Looking at that chart in the article, not too surprised the rest of the market in big red territory.
- sithadmin 7y ago>Achaogen ($AKAO) and Paratek ($PRTK) both had NDAs approved for novel antibiotics and saw their stock prices drop sharply in response to the news, as investors anticipated all those pesky expenses related to commercialization. I was around for most of Achaogen's implosion. Some key points not mentioned in this blog post: 1.) In the ~12 months leading up to FDA approval, Achaogen started burning their capital at a rate that was, frankly, insane. Financial decision-makers were definitely counting their chickens before they hatched, and this ultimately seems to have resulted in massive cuts to opex (e.g. sales positions) that snowballed into abysmal revenue once Zemdri hit the market. 2.) The FDA approved Achaogen's product, Zemdri, indication for complex UTIs (cUTI), but not for bloodstream infections (BSI). The latter indication is much more lucrative. My personal opinion is that this factor alone wasn't responsible for the poor sales numbers, but it was certainly a huge contributor to the problem.
- LatteLazy 7y agoThere's no guarantee that there even are further broad spectrum antibiotics possible. As far as I understand, what's needed here is (first) fundamental research, then discussion of promising ideas, then maybe you can rely on private companies to perfect and bring to market new molecules. Thats a far cry from other drugs for other diseases where there is a futile set of fundamentals to pick over and small research groups spinning off from universities regulatly. Every time I've heard of new prospects, it's either been reexamining old methods (like plagues) or new fundamental work (sampling and sequencing new bacteria, studies on fungi). So instead of "incentives", we should just man up and fund some biology and stop wasting what we have already on farm animal fattening programs and the worried well etc.
- rshnotsecure 7y agoSo much of the modern corporation has been outsourced...including nearly all research. Most animal research today and Phase II trials are done...in China/India. The evidence that these studies are largely faked due to the pressure put on the staff and management there has been piling up for years. I would recommend “Science Mart: Privatizing American Science” by Philip Mirowski for more on this.
- dmix 7y ago> and that larger players would correspondingly re-enter the market, hungry to pick up first-in-class antibiotic programs. Does this mean their business model is basically always going to be getting acquired by one of the big pharma firms?
- s1artibartfast 7y agoYes, This is essentially the only model in Pharma and bio-med.
- ggm 7y agoPublic fund, public production. Take antibiotics research out of the IPR domain, and put it back into public health funding.